{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:35:55Z","timestamp":1791866155692,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA168524"],"award-info":[{"award-number":["P30 CA168524"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006727","name":"Kansas University | University of Kansas Medical Center","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100006727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced epithelial ovarian cancer (EOC) survival rates are dishearteningly low, with ~25% surviving beyond 5 years. Evidence suggests that cancer stem cells contribute to acquired chemoresistance and tumor recurrence. Here, we show that IRAK1 is upregulated in EOC tissues, and enhanced expression correlates with poorer overall survival. Moreover, low molecular weight hyaluronic acid, which is abundant in malignant ascites from patients with advanced EOC, induced IRAK1 phosphorylation leading to STAT3 activation and enhanced spheroid formation. Knockdown of <jats:italic>IRAK1<\/jats:italic> impaired tumor growth in peritoneal disease models, and impaired HA-induced spheroid growth and STAT3 phosphorylation. Finally, we determined that TCS2210, a known inducer of neuronal differentiation in mesenchymal stem cells, is a selective inhibitor of IRAK1. TCS2210 significantly inhibited EOC growth in vitro and in vivo both as monotherapy, and in combination with cisplatin. Collectively, these data demonstrate IRAK1 as a druggable target for EOC.<\/jats:p>","DOI":"10.1038\/s41419-024-06717-3","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T11:01:39Z","timestamp":1716634899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"David","family":"Standing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Dandawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Gunewardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obdulia","family":"Covarrubias-Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine F.","family":"Roby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossama","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Bossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-9580","authenticated-orcid":false,"given":"Andrew K.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8020-434X","authenticated-orcid":false,"given":"Scott J.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-2281","authenticated-orcid":false,"given":"Roy A.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4193-3053","authenticated-orcid":false,"given":"Shrikant","family":"Anant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"6717_CR1","doi-asserted-by":"publisher","first-page":"e25976","DOI":"10.2196\/25976","volume":"7","author":"SP Yang","year":"2021","unstructured":"Yang SP, Su HL, Chen XB, Hua L, Chen JX, Hu M, et al. Long-term survival among histological subtypes in advanced epithelial ovarian cancer: population-based study using the surveillance, epidemiology, and end results database. JMIR Public Health Surveill. 2021;7:e25976.","journal-title":"JMIR Public Health Surveill"},{"key":"6717_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/bjc.2016.311","volume":"115","author":"GE Konecny","year":"2016","unstructured":"Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016;115:1157\u201373.","journal-title":"Br J Cancer"},{"key":"6717_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120:612\u20138.","journal-title":"Obstet Gynecol"},{"key":"6717_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/0008-5472.CAN-10-3220","volume":"71","author":"T Borovski","year":"2011","unstructured":"Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71:634\u20139.","journal-title":"Cancer Res"},{"key":"6717_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","volume":"16","author":"V Plaks","year":"2015","unstructured":"Plaks V, Kong N, Werb Z. The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225\u201338.","journal-title":"Cell Stem Cell"},{"key":"6717_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/aps.2013.27","volume":"34","author":"K Chen","year":"2013","unstructured":"Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732\u201340.","journal-title":"Acta Pharmacol Sin"},{"key":"6717_CR7","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.gore.2022.101018","volume":"42","author":"M Sanchez-Prieto","year":"2022","unstructured":"Sanchez-Prieto M, Sanchez-Borrego R, Lubian-Lopez DM, Perez-Lopez FR. Etiopathogenesis of ovarian cancer. An inflamm-aging entity? Gynecol Oncol Rep. 2022;42:101018.","journal-title":"Gynecol Oncol Rep"},{"key":"6717_CR8","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.3390\/cancers14163998","volume":"14","author":"D Wang","year":"2022","unstructured":"Wang D, Li Y, Ge H, Ghadban T, Reeh M, Gungor C. The extracellular matrix: a key accomplice of cancer stem cell migration, metastasis formation, and drug resistance in PDAC. Cancers (Basel). 2022;14:3998.","journal-title":"Cancers (Basel)"},{"key":"6717_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/genes4020101","volume":"4","author":"U Moens","year":"2013","unstructured":"Moens U, Kostenko S, Sveinbjornsson B. The Role of mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation. Genes (Basel). 2013;4:101\u201333.","journal-title":"Genes (Basel)"},{"key":"6717_CR10","doi-asserted-by":"publisher","first-page":"e50867","DOI":"10.1371\/journal.pone.0050867","volume":"7","author":"SM Smith","year":"2012","unstructured":"Smith SM, Cai L. Cell specific CD44 expression in breast cancer requires the interaction of AP-1 and NFkappaB with a novel cis-element. PLoS One. 2012;7:e50867.","journal-title":"PLoS One"},{"key":"6717_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4161\/cc.23406","volume":"12","author":"I Chefetz","year":"2013","unstructured":"Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle. 2013;12:511\u201321.","journal-title":"Cell Cycle"},{"key":"6717_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cyto.2015.02.025","volume":"74","author":"D De Nardo","year":"2015","unstructured":"De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine. 2015;74:181\u20139.","journal-title":"Cytokine."},{"key":"6717_CR13","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1073\/pnas.89.7.3070","volume":"89","author":"AK Godwin","year":"1992","unstructured":"Godwin AK, Meister A, O\u2019Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992;89:3070\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6717_CR14","first-page":"5225","volume":"53","author":"K Hamaguchi","year":"1993","unstructured":"Hamaguchi K, Godwin AK, Yakushiji M, O\u2019Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993;53:5225\u201332.","journal-title":"Cancer Res"},{"key":"6717_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.","journal-title":"Signal Transduct Target Ther"},{"key":"6717_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/brv.12293","volume":"92","author":"ZF Bielecka","year":"2017","unstructured":"Bielecka ZF, Maliszewska-Olejniczak K, Safir IJ, Szczylik C, Czarnecka AM. Three-dimensional cell culture model utilization in cancer stem cell research. Biol Rev Camb Philos Soc. 2017;92:1505\u201320.","journal-title":"Biol Rev Camb Philos Soc"},{"key":"6717_CR17","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1158\/0008-5472.CAN-17-3993","volume":"78","author":"J Hirst","year":"2018","unstructured":"Hirst J, Pathak HB, Hyter S, Pessetto ZY, Ly T, Graw S, et al. Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties. Cancer Res. 2018;78:4370\u201385.","journal-title":"Cancer Res"},{"key":"6717_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research N.","year":"2011","unstructured":"Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature."},{"key":"6717_CR19","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","volume":"69","author":"W Sakai","year":"2009","unstructured":"Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009;69:6381\u20136.","journal-title":"Cancer Res"},{"key":"6717_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.31083\/j.rcm2303097","volume":"23","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, He JQ. Interleukin receptor associated kinase 1 signaling and its association with cardiovascular diseases. Rev Cardiovasc Med. 2022;23:97.","journal-title":"Rev Cardiovasc Med"},{"key":"6717_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12026-014-8495-2","volume":"58","author":"SM Ruppert","year":"2014","unstructured":"Ruppert SM, Hawn TR, Arrigoni A, Wight TN, Bollyky PL. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. Immunol Res. 2014;58:186\u201392.","journal-title":"Immunol Res"},{"key":"6717_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1527-3466.2006.00261.x","volume":"24","author":"A Lochner","year":"2006","unstructured":"Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev. 2006;24:261\u201374.","journal-title":"Cardiovasc Drug Rev"},{"key":"6717_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/jcp.24171","volume":"228","author":"JM Kim","year":"2013","unstructured":"Kim JM, Choi JS, Kim YH, Jin SH, Lim S, Jang HJ, et al. An activator of the cAMP\/PKA\/CREB pathway promotes osteogenesis from human mesenchymal stem cells. J Cell Physiol. 2013;228:617\u201326.","journal-title":"J Cell Physiol"},{"key":"6717_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39116-2","volume":"9","author":"K Limbutara","year":"2019","unstructured":"Limbutara K, Kelleher A, Yang CR, Raghuram V, Knepper MA. Phosphorylation changes in response to kinase inhibitor H89 in PKA-null cells. Sci Rep. 2019;9:2814.","journal-title":"Sci Rep"},{"key":"6717_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/0003-4819-129-1-199807010-00009","volume":"129","author":"BA Neuschwander-Tetri","year":"1998","unstructured":"Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38\u201341.","journal-title":"Ann Intern Med"},{"key":"6717_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1023\/A:1005405526283","volume":"45","author":"EJ Murphy","year":"2000","unstructured":"Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, et al. Troglitazone-induced fulminant hepatic failure. Acute liver failure study group. Dig Dis Sci. 2000;45:549\u201353.","journal-title":"Dig Dis Sci"},{"key":"6717_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J."},{"key":"6717_CR28","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1039\/C9BM00895K","volume":"7","author":"SY Lee","year":"2019","unstructured":"Lee SY, Hong EH, Jeong JY, Cho J, Seo JH, Ko HJ, et al. Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma. Biomater Sci. 2019;7:4624\u201335.","journal-title":"Biomater Sci"},{"key":"6717_CR29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"6717_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms23020833","volume":"23","author":"S Capellero","year":"2022","unstructured":"Capellero S, Erriquez J, Battistini C, Porporato R, Scotto G, Borella F, et al. Ovarian cancer cells in ascites form aggregates that display a hybrid epithelial-mesenchymal phenotype and allows survival and proliferation of metastasizing cells. Int J Mol Sci. 2022;23:833.","journal-title":"Int J Mol Sci"},{"key":"6717_CR31","doi-asserted-by":"crossref","first-page":"E514","DOI":"10.1073\/pnas.1620139114","volume":"114","author":"E Della Mina","year":"2017","unstructured":"Della Mina E, Borghesi A, Zhou H, Bougarn S, Boughorbel S, Israel L, et al. Inherited human IRAK-1 deficiency selectively impairs TLR signaling in fibroblasts. Proc Natl Acad Sci USA. 2017;114:E514\u2013E23.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6717_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bjc.2014.513","volume":"112","author":"GW Rhyasen","year":"2015","unstructured":"Rhyasen GW, Starczynowski DT. IRAK signalling in cancer. Br J Cancer. 2015;112:232\u20137.","journal-title":"Br J Cancer"},{"key":"6717_CR33","doi-asserted-by":"publisher","first-page":"51697","DOI":"10.1074\/jbc.M410369200","volume":"279","author":"Y Huang","year":"2004","unstructured":"Huang Y, Li T, Sane DC, Li L. IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem. 2004;279:51697\u2013703.","journal-title":"J Biol Chem"},{"key":"6717_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cancers12010024","volume":"12","author":"CJ Wu","year":"2019","unstructured":"Wu CJ, Sundararajan V, Sheu BC, Huang RY, Wei LH. Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: mechanism and therapeutic opportunity. Cancers (Basel). 2019;12:24.","journal-title":"Cancers (Basel)"},{"key":"6717_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.7150\/jca.35011","volume":"11","author":"R Liang","year":"2020","unstructured":"Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y, et al. STAT3 signaling in ovarian cancer: a potential therapeutic target. J Cancer. 2020;11:837\u201348.","journal-title":"J Cancer"},{"key":"6717_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-476","volume":"13","author":"C Ricciardelli","year":"2013","unstructured":"Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer. 2013;13:476.","journal-title":"BMC Cancer"},{"key":"6717_CR37","first-page":"1733","volume":"148","author":"TK Yeo","year":"1996","unstructured":"Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol. 1996;148:1733\u201340.","journal-title":"Am J Pathol"},{"key":"6717_CR38","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1002\/1878-0261.13028","volume":"15","author":"Y Ding","year":"2021","unstructured":"Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B, et al. Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer. Mol Oncol. 2021;15:3578\u201395.","journal-title":"Mol Oncol"},{"key":"6717_CR39","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/polym12081800","volume":"12","author":"P Snetkov","year":"2020","unstructured":"Snetkov P, Zakharova K, Morozkina S, Olekhnovich R, Uspenskaya M. Hyaluronic acid: the influence of molecular weight on structural, physical, physico-chemical, and degradable properties of biopolymer. Polymers (Basel). 2020;12:1800.","journal-title":"Polymers (Basel)"},{"key":"6717_CR40","doi-asserted-by":"publisher","first-page":"12925","DOI":"10.3390\/ijms131012925","volume":"13","author":"I Weiss","year":"2012","unstructured":"Weiss I, Trope CG, Reich R, Davidson B. Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure. Int J Mol Sci. 2012;13:12925\u201338.","journal-title":"Int J Mol Sci"},{"key":"6717_CR41","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc1391","volume":"4","author":"BP Toole","year":"2004","unstructured":"Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528\u201339.","journal-title":"Nat Rev Cancer"},{"key":"6717_CR42","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10555-014-9532-2","volume":"33","author":"A Schmaus","year":"2014","unstructured":"Schmaus A, Bauer J, Sleeman JP. Sugars in the microenvironment: the sticky problem of HA turnover in tumors. Cancer Metastasis Rev. 2014;33:1059\u201379.","journal-title":"Cancer Metastasis Rev"},{"key":"6717_CR43","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.lfs.2007.02.037","volume":"80","author":"KS Girish","year":"2007","unstructured":"Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci. 2007;80:1921\u201343.","journal-title":"Life Sci"},{"key":"6717_CR44","doi-asserted-by":"publisher","first-page":"971278","DOI":"10.3389\/fimmu.2022.971278","volume":"13","author":"W Donelan","year":"2022","unstructured":"Donelan W, Dominguez-Gutierrez PR, Kusmartsev S. Deregulated hyaluronan metabolism in the tumor microenvironment drives cancer inflammation and tumor-associated immune suppression. Front Immunol. 2022;13:971278.","journal-title":"Front Immunol"},{"key":"6717_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38031-2","volume":"9","author":"B Zhou","year":"2019","unstructured":"Zhou B, Sun C, Huang J, Xia M, Guo E, Li N. et al. The biodiversity composition of microbiome in ovarian carcinoma patients. Sci Rep. 2019;9:1691.","journal-title":"Sci Rep"},{"key":"6717_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0603-4","volume":"13","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhao L, Han L, Fu G, Tuo X, Ma S, et al. The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. J Ovarian Res. 2020;13:8.","journal-title":"J Ovarian Res"},{"key":"6717_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9746","volume":"6","author":"ZN Wee","year":"2015","unstructured":"Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015;6:8746.","journal-title":"Nat Commun"},{"key":"6717_CR48","doi-asserted-by":"publisher","first-page":"904959","DOI":"10.3389\/fmolb.2022.904959","volume":"9","author":"M Liu","year":"2022","unstructured":"Liu M, Que Y, Hong Y, Zhang L, Zhang X, Zhang Y. A pan-cancer analysis of IRAK1 Expression and their association with immunotherapy response. Front Mol Biosci. 2022;9:904959.","journal-title":"Front Mol Biosci"},{"key":"6717_CR49","first-page":"6497241","volume":"2022","author":"J Li","year":"2022","unstructured":"Li J, Sun Y, Ma Y, Zhao X, Sun X, Wang Y, et al. Comprehensive pan-cancer analysis of IRAK family genes identifies IRAK1 as a novel oncogene in low-grade glioma. J Oncol. 2022;2022:6497241.","journal-title":"J Oncol"},{"key":"6717_CR50","doi-asserted-by":"publisher","first-page":"10878","DOI":"10.1021\/acs.jmedchem.1c00103","volume":"64","author":"L Fu","year":"2021","unstructured":"Fu L, Zhang J, Shen B, Kong L, Liu Y, Tu W, et al. Discovery of highly potent and selective IRAK1 degraders to probe scaffolding functions of IRAK1 in ABC DLBCL. J Med Chem. 2021;64:10878\u201389.","journal-title":"J Med Chem"},{"key":"6717_CR51","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1158\/0008-5472.CAN-12-0337","volume":"72","author":"R Srivastava","year":"2012","unstructured":"Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, et al. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012;72:6209\u201316.","journal-title":"Cancer Res"},{"key":"6717_CR52","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1194\/jlr.M045658","volume":"55","author":"RL Tiwari","year":"2014","unstructured":"Tiwari RL, Singh V, Singh A, Rana M, Verma A, Kothari N, et al. PKCdelta-IRAK1 axis regulates oxidized LDL-induced IL-1beta production in monocytes. J Lipid Res. 2014;55:1226\u201344.","journal-title":"J Lipid Res"},{"key":"6717_CR53","doi-asserted-by":"publisher","first-page":"22513","DOI":"10.1074\/jbc.M708319200","volume":"283","author":"Y Kim","year":"2008","unstructured":"Kim Y, Lee YS, Choe J, Lee H, Kim YM, Jeoung D. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem. 2008;283:22513\u201328.","journal-title":"J Biol Chem"},{"key":"6717_CR54","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1182\/blood-2022-167526","volume":"140","author":"J Bennett","year":"2022","unstructured":"Bennett J, Yeung J, Sampson A, Hueneman K, Wunderlich M, Choi K, et al. IRAK1 contributes to IRAK4 inhibitor resistance via non-canonical signaling mechanisms in MDS\/AML. Blood. 2022;140:2240\u20131.","journal-title":"Blood."},{"key":"6717_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1126\/scisignal.adh3449","volume":"16","author":"Y Li","year":"2023","unstructured":"Li Y, Shah RB, Sarti S, Belcher AL, Lee BJ, Gorbatenko A, et al. A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR\/IL-1R signaling. Sci. Signal. 2023;16:18.","journal-title":"Sci. Signal"},{"key":"6717_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41556-018-0260-7","volume":"21","author":"PH Liu","year":"2019","unstructured":"Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, et al. An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nat Cell Biol. 2019;21:203\u201313.","journal-title":"Nat Cell Biol"},{"key":"6717_CR57","doi-asserted-by":"publisher","first-page":"13507","DOI":"10.1073\/pnas.1714386114","volume":"114","author":"L Wang","year":"2017","unstructured":"Wang L, Qiao Q, Ferrao R, Shen C, Hatcher JM, Buhrlage SJ, et al. Crystal structure of human IRAK1. Proc Natl Acad Sci USA. 2017;114:13507\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6717_CR58","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1021\/acsmedchemlett.0c00378","volume":"11","author":"JM Hatcher","year":"2020","unstructured":"Hatcher JM, Yang G, Wang L, Ficarro SB, Buhrlage S, Wu H, et al. Discovery of a selective, covalent IRAK1 inhibitor with antiproliferative activity in MYD88 mutated B-cell lymphoma. ACS Med Chem Lett. 2020;11:2238\u201343.","journal-title":"ACS Med Chem Lett"},{"key":"6717_CR59","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100\u201322.","journal-title":"Nat Protoc"},{"key":"6717_CR60","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","volume":"17","author":"J Karlsson","year":"2020","unstructured":"Karlsson J, Rhodes KR, Green JJ, Tzeng SY. Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities. Expert Opin Drug Deliv. 2020;17:1395\u2013410.","journal-title":"Expert Opin Drug Deliv"},{"key":"6717_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"6717_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-1759(87)90407-8","volume":"105","author":"A Alcina","year":"1987","unstructured":"Alcina A, Fresno M. A colorimetric assay based on cell viability for the indirect detection of intracellular replication and killing of Trypanosoma cruzi. J Immunol Methods. 1987;105:1\u20138.","journal-title":"J Immunol Methods"},{"key":"6717_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics."},{"key":"6717_CR64","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics."},{"key":"6717_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"6717_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361.","journal-title":"J Comput Chem"},{"key":"6717_CR67","first-page":"13","volume":"2011","author":"N Alexander","year":"2011","unstructured":"Alexander N, Woetzel N, Meiler J. bcl::Cluster : a method for clustering biological molecules coupled with visualization in the pymol molecular graphics system. IEEE Int Conf Comput Adv Bio Med Sci. 2011;2011:13\u20138.","journal-title":"IEEE Int Conf Comput Adv Bio Med Sci"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06717-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T12:04:01Z","timestamp":1716638641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06717-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["6717"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06717-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to disclose. All data needed to evaluate the conclusions in the paper are present in the paper and\/or the Supplementary Materials. RNA-sequencing data will be made available in the NCBI GEO Database. The Institutional Animal Care and Use Committee (IACUC) at the University of Kansas Medical Center approved all animal studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Human patients were not used and therefore is not applicable to our studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate statement"}}],"article-number":"362"}}